Evidence map›Paper›PMID 39288010›Full record

ArticleThe Journal of clinical endocrinology and metabolism2025

PCSK1N as a Tumor Size Marker and an ER Stress Response Protein in Corticotroph Pituitary Adenomas.

Merisa Abusdal, Kjersti R Normann, Tuula A Nyman, Kristin A B Øystese, Arvind Y M Sundaram, Daniel Dahlberg, Tove Lekva, Jens Bollerslev, Jens P Berg, Nicoleta C Olarescu

Abstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Phosphoproteomic dysregulation promotes tumor proliferation in Cushing's disease.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Merisa AbusdalSection of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital (OUS), 0424 Oslo, Norway.ORCID 0009-0001-8460-9117
Kjersti R NormannSection of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital (OUS), 0424 Oslo, Norway.
Tuula A NymanDepartment of Immunology, OUS and University of Oslo, 0424 Oslo, Norway.ORCID 0000-0001-8787-5886
Kristin A B ØysteseSection of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital (OUS), 0424 Oslo, Norway.ORCID 0000-0002-3147-6007
Arvind Y M SundaramDepartment of Medical Genetics, OUS and University of Oslo, 0424 Oslo, Norway.ORCID 0000-0002-3007-7784
Daniel DahlbergDepartment of Neurosurgery, OUS, 0424 Oslo, Norway.ORCID 0000-0001-5278-1978
Tove LekvaResearch Institute of Internal Medicine, OUS, 0424 Oslo, Norway.ORCID 0000-0002-7962-4726
Jens BollerslevSection of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital (OUS), 0424 Oslo, Norway.ORCID 0000-0002-0654-4610
Jens P BergInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway.ORCID 0000-0003-0157-5888
Nicoleta C OlarescuSection of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital (OUS), 0424 Oslo, Norway.ORCID 0009-0004-9436-539X

Funding

Research Council of Norway INFRASTRUKTUR-program 295910South-Eastern Norway Regional Health Authority 2020081/2020
6 · The paper itself

Abstract

contextSilent corticotroph adenoma (SCA) exhibits more tumor aggressiveness features than functioning adenomas (FCAs).

objectiveWe aimed to investigate proprotein convertase subtilisin/kexin type 1 inhibitor (PCSK1N) expression in CA and examine if endoplasmic reticulum (ER) stress-induced responses affect cell survival in a corticotroph tumor cell model.

methodsClinical and imaging characteristics were recorded in 33 patients with FCA (20 women, 11 macroadenomas) and 18 SCAs (8 women, all macroadenomas). Gene expression of pro-opiomelanocortin (POMC), T-box transcription factor 19(TBX19)/TPIT, proprotein convertase subtilisin/kexin type 1 (PCSK1)/PC1/3, and its inhibitor PCSK1N, was measured by reverse transcription-quantitative polymerase chain reaction in adenoma tissue. Mouse pituitary corticotroph tumor (AtT-20) cells were treated with tanespimycin (17-AAG), an HSP90 chaperone inhibitor, to induce ER stress, followed by gene and protein analyses.

resultsPOMC, TPIT, and PCSK1 expression were higher, whereas PCSK1N was lower in FCA compared to SCA. PCSK1N correlated with POMC (rs = -0.514; P < .001), TPIT (rs = -0.386; P = .005), PCSK1 (rs = -0.3691; P = .008), and tumor largest diameter (rs = 0.645; P < .001), in all CA. Induction of ER stress by 17-AAG in AtT-20 cells led to a decrease of Pomc and an increase of Pcsk1n gene expression at 24 hours. Moreover, a downregulation of cell cycle, apoptosis, and senescence pathways, and alterations in cell adhesion and cytoskeleton, were observed at the protein level.

conclusionPCSK1N is higher in SCA compared with FCA, and associated with corticotroph cell markers and tumor size. PCSK1N is likely to be part of the adaptive response to ER stress, potentially conferring a survival advantage to the corticotroph tumor cell in conjunction with other proteins.

Indexed as

ACTH-Secreting Pituitary AdenomaAdenomaBiomarkers, TumorEndoplasmic Reticulum StressPituitary NeoplasmsAdultAgedAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMiddle AgedPro-OpiomelanocortinBiomarkers, TumorPro-OpiomelanocortinProprotein Convertase 1Cushing diseasenonfunctioning pituitary adenomapro-opiomelanocortinproSAASunfolded protein response

Identifiers

PMID39288010
PMCPMC11913095

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.